Fig 1.
Stability of eosinophil-derived neurotoxin at ambient temperature.
(A) venous whole blood from healthy subjects (n = 3) and (B) serum from healthy subjects (n = 7). Group means are shown with standard deviations.
Table 1.
5 serum samples containing EDN were incubated with 5 different polypropylene tubes for 2hr at ambient temperature. ND: not determined.
Table 2.
Stability of serum eosinophil-derived neurotoxin.
Samples from 7 healthy volunteers were tested every day for short term stability and freeze/thaw, and every three months for long term stability. During the testing period the mean sample values should not exceed ± 15% the baseline value taken when the serum was prepared.
Fig 2.
The effect of atopy and smoking on eosinophil and eosinophil-derived neurotoxin levels in healthy subjects.
A) blood eosinophils (B) serum EDN where HNS-A, healthy non-smoker atopic; HNS-NA, healthy non-smoker non-atopic; HS-A, healthy smoker atopic; HS-NA, healthy smoker non-atopic. Group means are shown with 95% CI and each cohort had 20 subjects.
Fig 3.
Temporal variation in eosinophil and eosinophil-derived neurotoxin levels.
An EOS or EDN ratio of 1.00 indicates there is no difference in mean between that timepoint and the mean level at 12:00h for (A) blood eosinophils (B) serum EDN for (▲) healthy (n = 10) and (●) mild/moderate asthma subjects (n = 20). Group means are shown with 95% CI.
Fig 4.
Scatter dot plot showing the comparison of eosinophil-derived neurotoxin levels in donor derived cells: Eosinophils, neutrophils, monocytes (n = 7) and hepatocytes and alveolar macrophages (n = 2).
Group means are shown with standard deviations.